JP2023541007A5 - - Google Patents
Info
- Publication number
- JP2023541007A5 JP2023541007A5 JP2023515155A JP2023515155A JP2023541007A5 JP 2023541007 A5 JP2023541007 A5 JP 2023541007A5 JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023541007 A5 JP2023541007 A5 JP 2023541007A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- acetylglucosamine
- approximately
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074602P | 2020-09-04 | 2020-09-04 | |
| US63/074,602 | 2020-09-04 | ||
| US202163142669P | 2021-01-28 | 2021-01-28 | |
| US63/142,669 | 2021-01-28 | ||
| PCT/US2021/048991 WO2022051575A2 (en) | 2020-09-04 | 2021-09-03 | Compounds and methods for treating viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541007A JP2023541007A (ja) | 2023-09-27 |
| JP2023541007A5 true JP2023541007A5 (https=) | 2024-09-12 |
Family
ID=80491477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515155A Pending JP2023541007A (ja) | 2020-09-04 | 2021-09-03 | ウイルス感染処置のための化合物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230346816A1 (https=) |
| EP (1) | EP4208137A4 (https=) |
| JP (1) | JP2023541007A (https=) |
| CA (1) | CA3194024A1 (https=) |
| MX (1) | MX2023002667A (https=) |
| TW (1) | TW202228730A (https=) |
| WO (1) | WO2022051575A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202239417A (zh) * | 2021-01-29 | 2022-10-16 | 艾米爾 Ｅ 哈森 | 預防病毒感染之方法 |
| CN119156219A (zh) * | 2022-04-21 | 2024-12-17 | 塞拉珀蒂科什股份有限公司 | 治疗发炎的方法 |
| GB2628963A (en) * | 2023-02-08 | 2024-10-16 | Univ Of Lincoln | Formulations and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1533776A (zh) * | 2003-03-27 | 2004-10-06 | 中国人民解放军第三军医大学 | N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用 |
| CN101227916A (zh) * | 2005-05-24 | 2008-07-23 | 维尔金有限公司 | 预防和治疗发炎相关状况的组合物和方法 |
| WO2011046057A1 (ja) * | 2009-10-15 | 2011-04-21 | 独立行政法人産業技術総合研究所 | シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物 |
| JP5807895B2 (ja) * | 2011-02-17 | 2015-11-10 | 学校法人慶應義塾 | Ｈｃｖｒｎａ複製抑制剤 |
| CA2832859C (en) * | 2011-04-15 | 2020-06-16 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
| CN107281199A (zh) * | 2017-07-27 | 2017-10-24 | 吉林省始祖生物波医学研究院有限公司 | N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物 |
-
2021
- 2021-09-03 MX MX2023002667A patent/MX2023002667A/es unknown
- 2021-09-03 JP JP2023515155A patent/JP2023541007A/ja active Pending
- 2021-09-03 EP EP21865159.4A patent/EP4208137A4/en active Pending
- 2021-09-03 US US18/024,399 patent/US20230346816A1/en active Pending
- 2021-09-03 CA CA3194024A patent/CA3194024A1/en active Pending
- 2021-09-03 WO PCT/US2021/048991 patent/WO2022051575A2/en not_active Ceased
- 2021-09-03 TW TW110132929A patent/TW202228730A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP3701870B2 (ja) | 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ | |
| JP2023541007A5 (https=) | ||
| US6335021B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| Zosel et al. | Severe lactic acidosis after an iatrogenic propylene glycol overdose | |
| JP2022521233A5 (https=) | ||
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| US20030195255A1 (en) | Method for treating hepatic encephalopathies | |
| JP2023548429A5 (https=) | ||
| Hall et al. | Rapid deterioration in patients with parkinsonism following tryptophan‐pyridoxine administration | |
| HUT56496A (en) | Process for producing pharmaceutical compositions comprising buspirone, suitable for treating apnoea arising during sleep | |
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP3227578B2 (ja) | 睡眠誘起性無呼吸症治療剤 | |
| JPH06172187A (ja) | 筋ジストロフィー症治療薬 | |
| US20200085849A1 (en) | Methods and compositions for improving sleep | |
| JP2021509671A5 (https=) | ||
| Kim et al. | The alternative of oral sedation for pediatric dental care | |
| Ehgartner et al. | Hemodynamic instability following intentional nadolol overdose | |
| Sathaporn et al. | A Rare Cause of Refractory Vasodilatory Shock Due to Calcium Channel Blocker Toxicity from Drug-Drug Interaction Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) And Manidipine | |
| CN112641765B (zh) | 丙泊酚的抗疲劳制药用途 | |
| RU2457834C1 (ru) | Способ лечения метаболического синдрома | |
| Cholewa et al. | Effects of naloxone on ethanol-induced coma | |
| Chander et al. | Adriamycin induced pulseless electrical activity and cardiovascular collapse during general anesthesia for ventriculo-peritoneal shunt insertion |